Jagged Ligands Enhance the Pro-Angiogenic Activity of Multiple Myeloma Cells
Maria Teresa Palano(University of Milan), Raffaella Chiaramonte(University of Milan), M. Colombo(Human Technopole), Ilaria Saltarella(University of Bari Aldo Moro), Antonino Neri(University of Milan), Monica Falleni(University of Milan), Domenica Giannandrea(University of Milan), Elena Lesma(Ospedale San Paolo), Valentina Citro(University of Naples Federico II), Elisa Taìana(University of Milan), Germano Gaudenzi(IRCCS Istituto Auxologico Italiano), Giovanni Vitale(University of Milan), Nicola Amodio(Magna Graecia University), Delfina Tosi(University of Milan), Natalia Platonova(University of Milan), Roberto Ria(University of Bari Aldo Moro)
Cited by 11
Related Papers
International Myeloma Working Group molecular classification of multiple myeloma: spotlight review
|Leukemia|2009|877
Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia
|Blood|2015|216
Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated Follow-Up and Improved Survival
|Journal of Clinical Oncology|2014|210
Oncogenic Role of the E3 Ubiquitin Ligase NEDD4-1, a PTEN Negative Regulator, in Non-Small-Cell Lung Carcinomas
|American Journal Of Pathology|2010|159